BiotechTube

HMPL-453 + Rabeprazole

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma

Trial Timeline

Mar 17, 2023 → Aug 28, 2023

NCT ID
NCT05930119

About HMPL-453 + Rabeprazole

HMPL-453 + Rabeprazole is a phase 1 stage product being developed by HUTCHMED for Intrahepatic Cholangiocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05930119. Target conditions include Intrahepatic Cholangiocarcinoma.

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholangiocarcinoma were approved

Approved (0) Terminated (1) Active (3)
🔄A4250 (odevixibat)IpsenPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
🔄MaralixibatMirum PharmaceuticalsPhase 3
❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05930119Phase 1Completed

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
31
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
42
ApatinibJiangsu Hengrui MedicinePhase 2
35
FamitinibJiangsu Hengrui MedicinePhase 2
27
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
31
Durvalumab + SNDX-6352AstraZenecaPhase 2
35
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Pemigatinib + DurvalumabAstraZenecaPhase 2
42
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
42
PemigatinibIncytePhase 2
24
A4250 (odevixibat)IpsenPhase 3
37
OdevixibatIpsenPre-clinical
23
CGT4859Cogent BiosciencesPhase 1/2
36
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
32
MaralixibatMirum PharmaceuticalsPhase 3
37
MaralixibatMirum PharmaceuticalsPhase 2
39
MaralixibatMirum PharmaceuticalsPhase 2
32
Volixibat + PlaceboMirum PharmaceuticalsPhase 2
24
MaralixibatMirum PharmaceuticalsPhase 3
37
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
29